Key result
In vivo gene transfer of parvalbumin reduced left ventricular diastolic pressure and the time course of pressure decline in two aged rat models without affecting systolic parameters.
Why the study?
Does in vivo gene transfer of parvalbumin improve diastolic function in aged rat models?
Does in vivo gene transfer of parvalbumin improve diastolic function in aged rat models?
In vivo gene transfer of parvalbumin improves diastolic function in aged rat models, suggesting a potential gene therapy approach for age-related diastolic dysfunction.
Answers are grounded in this paper and cite their sources.
Parvalbumin gene transfer merits further animal studies; leaves open applicability to human age-related diastolic dysfunction.
OBJECTIVE: Diastolic dysfunction is a characteristic finding of the aged mammalian heart. Parvalbumin acts as a Ca2+ sink and enhances relaxation in skeletal muscle, and overexpression of parvalbumin in myocardium increased cardiac relaxation in vitro as well as in vivo. Therefore, the objective of this study is to test the hypothesis that in vivo gene transfer of parvalbumin will improve diastolic dysfunction in aged rat heart. METHODS: We used adenovirus to transfer parvalbumin into two different rat models of aging: the Fischer 344 (F344) and the Fischer 344 x Brown Norway F1 hybrid (F344 x BN). Cardiac function was measured and compared after gene transfer. RESULTS: In vivo overexpression of parvalbumin in both rat aging models had no effect on systolic parameters but reduced left ventricular diastolic pressure and the time course of pressure decline. Overexpression of parvalbumin also improved the force frequency relationship in senescent rats. CONCLUSION: In vivo overexpression of parvalbumin improves diastolic dysfunction in two rat models of senescence, and this effect is independent of the rat strain investigated. The results show promise that gene therapy of parvalbumin may address the impaired Ca2+ homeostasis and diastolic dysfunction without an increase in energy expenditure.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2004) studied Diastolic dysfunction. In vivo gene transfer of parvalbumin was evaluated on Cardiac function (systolic parameters, left ventricular diastolic pressure, time course of pressure decline). In vivo gene transfer of parvalbumin reduced left ventricular diastolic pressure and the time course of pressure decline in two aged rat models without affecting systolic parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: